U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235644) titled 'Comparison of Efficacy and Safety in Patients Switching From MabThera(R) to Rixathon(R) in Relapsing-Remitting Multiple Sclerosis' on Nov. 14.
Brief Summary: This observational study investigates if switching from MabThera(R) to Rixathon(R) is associated with changes in disease activity and/or safety in people with multiple sclerosis (MS).
The main questions it aims to answer are:
* Does switching to Rixathon(R) affect tissue damage, measured by blood levels of neurofilament light (pNfL)?
* Does switching to Rixathon(R) affect the number of new MRI lesions, relapses, or disability progression?
Researchers will look at health inf...